Pain Therapeutics (NASDAQ:PTIE) saw strong trading volume on Thursday . 204,577 shares were traded during mid-day trading, an increase of 69% from the previous session’s volume of 120,722 shares.The stock last traded at $2.50 and had previously closed at $2.37.

Separately, Zacks Investment Research lowered Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th.

The stock has a 50-day moving average of $2.18 and a 200-day moving average of $2.08. The company’s market capitalization is $117.66 million.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings data on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.07. On average, equities research analysts expect that Pain Therapeutics will post ($0.54) earnings per share for the current year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.